Vanguard Group Inc Omega Therapeutics, Inc. Transaction History

Vanguard Group Inc

$4.96 Trillion
Q1 2024

A detailed history of Vanguard Group Inc transactions in Omega Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,279,925 shares of OMGA stock, worth $2.65 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,279,925

Previous 1,509,188 15.19%

Holding current value

$2.65 Million

Previous $4.54 Million 2.84%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$2.73 - $5.32 $625,887 - $1.22 Million	-229,263 Reduced 15.19%	1,279,925 $4.67 Million
Q4 2023 Feb 14, 2024	BUY	$1.35 - $3.21 $31,796 - $75,605	23,553 Added 1.59%	1,509,188 $4.54 Million
Q3 2023 Nov 14, 2023	BUY	$2.15 - $5.68 $3,037 - $8,025	1,413 Added 0.1%	1,485,635 $3.19 Million
Q2 2023 Aug 14, 2023	BUY	$5.6 - $9.66 $477,691 - $824,017	85,302 Added 6.1%	1,484,222 $8.31 Million
Q1 2023 May 15, 2023	BUY	$4.81 - $10.95 $2.04 Million - $4.64 Million	423,300 Added 43.39%	1,398,920 $8.44 Million

Q4 2022 Feb 10, 2023	SELL	$4.59 - $7.05 $71,278 - $109,479	-15,529 Reduced 1.57%	975,620 $5.57 Million
Q3 2022 Nov 14, 2022	BUY	$3.63 - $6.65 $876,739 - $1.61 Million	241,526 Added 32.22%	991,149 $5.37 Million
Q2 2022 Aug 12, 2022	SELL	$2.01 - $7.19 $206,388 - $738,276	-102,681 Reduced 12.05%	749,623 $2.85 Million
Q1 2022 May 13, 2022	BUY	$6.24 - $14.04 $3.18 Million - $7.15 Million	509,492 Added 148.62%	852,304 $5.32 Million
Q4 2021 Feb 14, 2022	BUY	$11.33 - $29.38 $120,143 - $311,545	10,604 Added 3.19%	342,812 $3.88 Million
Q3 2021 Nov 12, 2021	BUY	$16.0 - $22.51 $5.32 Million - $7.48 Million	332,208 New	332,208 $6.26 Million

Others Institutions Holding OMGA

# of Institutions

Shares Held

45.8M

Call Options Held

45.1K

Put Options Held

75.3K

View Full List

About Omega Therapeutics, Inc.

Ticker OMGA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,853,400
Market Cap $99.1M
Description
Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-...

More about OMGA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Omega Therapeutics, Inc. Transaction History